GGHC
PTLA

Gilder Gagnon Howe & Co’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-58,875
Closed -$2.51M – 274
2015
Q3 		$2.51M Sell
58,875
-54,823
-48% -$2.65M 0.04% 162
2015
Q2 		$5.18M Sell
113,698
-27,615
-20% -$1.11M 0.07% 153
2015
Q1 		$5.36M Buy
+141,313
New +$4.85M 0.07% 134

Other funds holding PTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Gilder Gagnon Howe & Co's PTLA Position: Q4 2015 in Review

Gilder Gagnon Howe & Co sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2015, closing a stake of 58,875 shares — an estimated $2.51M sold.

Gilder Gagnon Howe & Co first reported a position in PTLA in Q1 2015 and held it in 3 quarters. The position peaked at $5.36M in Q1 2015. 190 funds tracked by Wall St. Rank hold PTLA as of Q4 2015.

  • Gilder Gagnon Howe & Co reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 58,875 Portola Pharmaceuticals, Inc. shares in Q4 2015, an estimated $2.51M.
  • Gilder Gagnon Howe & Co first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 3 quarters.
  • Gilder Gagnon Howe & Co's Portola Pharmaceuticals, Inc. position peaked at $5.36M in Q1 2015.
  • 190 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2015, filed 4 Feb 2016.